HANSOH PHARMA (03692) rose more than 4% before noon. As of the time of writing, the stock was up 3.64%, trading at HK$42.12 with a turnover of HK$97.6223 million. On January 8, HANSOH PHARMA announced that its innovative drug Ameile® (Aumolertinib Mesilate Tablets) received a drug registration certificate from the National Medical Products Administration (NMPA) of China, approving the addition of a new indication. The new indication is for the first-line treatment of Ameile® in combination with pemetrexed and platinum-based chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations. This marks the fifth indication approved for Ameile®. Notably, according to a post on HANSOH PHARMA's official WeChat account, the latest research results for the company's innovative drug Ameile® (Aumolertinib Mesilate Tablets, 110mg) used as adjuvant therapy for EGFR-mutated NSCLC were recently published online in the prestigious international oncology journal *The Lancet Oncology* (Impact Factor: 35.9). The data showed that Ameile® significantly improved disease-free survival (DFS) in patients with completely resected stage II-IIIB EGFR-mutated NSCLC, while also demonstrating a favorable safety profile.